减低强度预处理造血干细胞移植治疗慢性淋巴细胞白血病与Richter转化
该回顾性分析纳入2006年9月至2017年4月在纪念斯隆凯特琳癌症中心接受减低强度预处理(RIC)造血干细胞移植(HSCT)的58例慢性淋巴细胞白血病(CLL)患者,其中23例为Richter转化(CLL-RT)。中位随访68个月,5年无进展生存(PFS)为40%(95%CI 28%-56%),总生存(OS)为58%(95%CI 48%-74%),1年无移植物抗宿主病/复发生存(GRFS)为38%(95%CI 25%-50%)。CLL-RT与无RT的CLL患者结局相当;治疗敏感反应和既往治疗线数≤3线者PFS和OS更优;含全身照射(TBI)的RIC方案PFS、OS和GRFS更差。
要点
- RIC-HSCT可使部分CLL及Richter转化患者获得长期生存,5年OS为58%。
- 治疗敏感且既往治疗线数≤3线的患者PFS和OS更优。
- 含TBI的RIC方案与更差的PFS、OS和GRFS相关,应谨慎使用。
核心结论
- RIC-HSCT对CLL-RT和 poor-risk CLL患者是一种可行的治疗选择,尤其在早期缓解阶段。
研究设计与样本
- 回顾性分析2006年9月至2017年4月在纪念斯隆凯特琳癌症中心接受RIC-HSCT的58例CLL患者,其中23例为CLL-RT。
主要发现
- 中位随访68个月(范围24-147个月),5年PFS为40%(95%CI 28%-56%),5年OS为58%(95%CI 48%-74%)。
- 1年GRFS为38%(95%CI 25%-50%)。
- CLL-RT与无RT的CLL患者结局相当。
- 治疗敏感反应和既往治疗线数≤3线者PFS和OS更优。
- 含TBI的RIC方案与更差的PFS、OS和GRFS相关。
关键数值与推荐
- CLL-RT患者中年龄>55岁且HSCT合并症指数评分≥2者OS更差。
临床怎么用
- 对于CLL-RT和 poor-risk CLL患者,可考虑在早期缓解阶段进行RIC-HSCT。
- 选择RIC方案时应谨慎使用含TBI的方案。
局限性
- 回顾性研究,样本量有限(58例),结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (HSCT) may potentially cure patients with chronic lymphocytic leukemia (CLL) and Richter's transformation (CLL-RT) or CLL without RT, but the impact of novel agents on HSCT is unclear. CLL-RT patients have a grave prognosis, and their outcomes after HSCT are uncertain. We conducted a retrospective analysis of all 58 CLL patients, including 23 CLL-RT patients, who underwent reduced intensity conditioning (RIC) HSCT at Memorial Sloan Kettering Cancer Center (New York, NY) between September 2006 and April 2017. With a median follow-up of 68 months (range, 24-147 months), 5-year progression-free survival (PFS) was 40% (95% confidence interval [CI], 28%-56%), and overall survival (OS) was 58% (95% CI, 48%-74%). The 1-year graft-versus-host disease/relapse-free survival (GRFS) was 38% (95% CI, 25%-50%). Patients with CLL-RT and CLL patients without RT had comparable outcomes. In both cohorts, treatment-sensitive response and ≤3 previous lines of therapy produced superior PFS and OS. Outcomes were agnostic to adverse cytogenetic and molecular features. Novel agents did not have a negative impact on HSCT outcomes. Total body irradiation (TBI)-containing RIC yielded inferior PFS, OS, and GRFS. CLL-RT patients older than age 55 years who had an HSCT Comorbidity Index score of ≥2 demonstrated inferior OS. This study, which is the largest series of RIC-HSCT for patients with CLL-RT, provides evidence supporting RIC-HSCT in early remission courses for patients with CLL-RT and poor-risk CLL patients. TBI-containing RIC should be considered with caution.
引用
- Lahoud OB, Devlin SM, Maloy MA, et al. Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. Blood Adv. 2021. PMID: 34297048. doi:10.1182/bloodadvances.2020003726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。